CN1341016A - Effervescent laxatives - Google Patents

Effervescent laxatives Download PDF

Info

Publication number
CN1341016A
CN1341016A CN00804156A CN00804156A CN1341016A CN 1341016 A CN1341016 A CN 1341016A CN 00804156 A CN00804156 A CN 00804156A CN 00804156 A CN00804156 A CN 00804156A CN 1341016 A CN1341016 A CN 1341016A
Authority
CN
China
Prior art keywords
preparation
peg
acid
effervescent
caccagogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00804156A
Other languages
Chinese (zh)
Inventor
B·P·达吉
K·G·曼德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CN1341016A publication Critical patent/CN1341016A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention is directed to a novel osmotic/effervescent system for the treatment of constipation and fecal impaction in a human or mammal in need thereof.

Description

Effervescent laxatives
Invention field
The present invention relates to a kind of new nonprescription drugs (OTC) caccagogue, as a kind of improved replacement therapy of present zest caccagogue.
Background of invention
In following 2～3 years, Food and Drug Administration (FDA) cancels the OTC approval to present several zest caccagogues probably.In the past decade, positive carcinogenecity and/or genetoxic result cause FDA to ban use of istizin (1980 mid-nineties 90), and in view of safety problem, FDA had removed the phenolphthalein as the OTC caccagogue from the OTC inventory in 1997.
Specifically, in June, 1998, FDA continued the kind of compression zest caccagogue, the stimulant Folium Sennae of remaining approved, Phamnus cathartica L., Aloe, bisacodyl reclassified from type i (safety and effectively) be type-iii (needing more data), and require maker that carcinogenecity and the genotoxic appraising datum nearest to these caccagogue active component is provided.If can not satisfy the requirement of these regulations and/or can not prove its safety then will cause these caccagogues further from experimental final entry (TFM), to be removed, (Fed.Reg.63:33592-33595, on June 19th, 1998).In fact, people such as Van Gorkom reach a conclusion in nearest one piece of scientific literature describes in detail: contain class anthrol (anthranoid) caccagogue of active part in the Folium Sennae extract and chemical caccagogue phenolphthalein bisacodyl the generation that promotes and cause tumor is all had latent effect, and may with the danger relevant (VanGorkom, the B.A.P. that increase colorectal carcinoma; De Vries, E.G.E.; Karrenbeld, A.; Kleibeuker, J.H. class anthraquinone caccagogue and potential carcinogenesis thereof.Alimentary Pharmacology ﹠amp; Therapeutics (digestive tract pharmacy and therapeutics), the 13rd volume, pp 443-452,1999.)。So the probability of the use that further is under an embargo is very big.
Therefore, this part market of OTC caccagogue has theatrical variation most probably in the coming years.If imitate FDA to ban use of the incident of the practice of phenolphthalein to take place once more, then other country will take any practice that FDA is imitated in similarly forbidding order.
Though can obtain fluffy fiber product, for example Metamucil at present And Citrucel , but most of individuals find that these products all have unacceptable product aesthetic (for example taste, viscosity, volume etc.).Therefore people wish to have the novel treatment based on easy use and aesthetic properties that substitutes these fluffy fiber caccagogues to come out.
Being used for carrying out before the operation of colonoscopy or gastrointestinal (GI) one group of newer replacement therapy agent that enteral cleans is that prescription drugs isoosmotic pressure enteral is got rid of medicinal liquid, for example Golytely And Nulytely (Braintree Labs, Braintree, MA, the U.S.).Similarly the prescription drugs product by Schwarz pharmaceuticals with Colyte Trade mark is sold in the U.S., then has commodity to be called Movicol in Europe The permeability caccagogue of (Norgine company limited, Middlesex, Britain) is sold.Recently, a kind of new caccagogue that contains Polyethylene Glycol 3350 NF also is introduced into the U.S. (Miralax , Braintree Labs, Braintree, MA, the U.S.), but this medicine can only be bought with prescription.
All these products all contain Polyethylene Glycol (PEG) as active component.In most of products, PEG mixes with various salt so that a kind of laxative action with Osmotic balance to be provided.When these products used with required large volume (2-4 liter) with colon flushing and cleaning, doing like this needed.When using large volume, these medicaments that contain PEG can clean fully to colon before GI operation or colonoscopy.These medicaments neither can stimulate power and water to separate matter to be secreted in the gastrointestinal pipeline, also can not cause tangible power and water to separate matter and absorb, and in fact, the liquid volume of absorption is just just by the gastrointestinal pipeline.Indicate as for the purposes of intestinal eliminant for this, allow the patient in several hours, drink the 2-4 liter.
Halow, the United States Patent (USP) 5,710,183 of G. discloses a kind of PEG compositions that contains fiber filling agent, is used for clinical treatment constipation and/or diarrhoea.
People's such as Castagnola United States Patent (USP) 5,124,144 discloses a kind of PEG/ electrolyte product as cathartic.
Fordtran, the WO 87/00754 of J. disclose a kind of low sodium caccagogue and irrigating solution, contain PEG, and have added various electrolyte, for example sodium, potassium, chloride and bicarbonate.
People's such as Deyhle DE 3807712 discloses a kind of laxative, also contains electrolyte, PEG, alkali metal hydrogencarbonate and citric acid.
People's such as Chumak RU 2111741 discloses low lavation volume, the i.e. 2 liters of methods that contain electrolytical PEG solution used.This electrolyte mixture contains sodium bicarbonate and citric acid, presents in an amount at least sufficient to produce effervescent.
People's such as Jacob WO 98/43654 relates to a kind of non-water colon abluent that contains magnesium salt and may contain Polyethylene Glycol.
The Japan Patent JP 4198126 of OTSUKA PHARM company limited discloses a kind of liquid preparation that contains PEG and electrolyte and a-amino acid that is used for coloclysis.This a-amino acid as antioxidant so that PEG is stable and prevent to form formaldehyde.The problem that this caccagogue that is based on PEG produces in its early production history.That nowadays use is highly purified PEG, so these problems have not existed.The product content of 0.01% scope (0.1g/l) also is too low, so that significant effervescent effect can not be provided.
Summary of the invention
The present invention relates to contain the pharmaceutical preparation of Polyethylene Glycol (PEG) 3350, and pharmaceutically acceptable effervescent coupling system.
Another aspect of the present invention is the said medicine preparation to the mammal effective dosage, is used for the treatment of the constipation in the mammal, or the method for treatment fecal impaction.
Detailed Description Of The Invention
The present invention relates to a kind of permeability intestinal eliminating vacuole and rise preparation, for example a kind of product based on polyvinyl alcohol.This class preparation provides a kind of acceptable cathartic effect level, has safer advantage with present comparing with regard to the stimulant of safety problem in the FDA examination.In addition, it should be safe in the department of pediatrics constipation therapy that this class preparation is used in, and is suitable.
This class effervescent/PEG infiltration preparation provides a kind of selection scheme, and this selection scheme provides a kind of new safety product conduct succedaneum of technology at present.It is not only safe but also be doctor's highly recommended that this infiltration preparation based on PEG has been proved to be.
But,,, for example needed only the dosage of 1 time or 2 times 4-8 ounce in 24 hours for the volume that as the OTC (over-the-counter) caccagogue, requires to consume much less based on the preparation of effervescent/PEG.Several pieces of research reports of having delivered have shown the purposes that is used as low volume dose caccagogue based on the technology of PEG.E.Corazziari, D.Badiali, F.L.Habib, G.Reboa, G.Pitto, G.Mazzacca, F.Sabbatini, R.Galeazzi, Te, Cilluffo, I.Vantini, E.Bardelli, the small size isoosmotic pressure polyethylene glycol electrolyte balance solution of using in the chronic non-organic constipation therapy of F.Baldi. (PMF-100).Digestive Diseases ﹠amp; Science (digestive tract disease and science), the 41st volume, 1636-1642 page or leaf, 1996.
J.A.DiPalma, P.H.deRidder, R.C.Orlando, B.E.Kolts, the multicenter study of a kind of control of placebo at random of the safety of M.v.B.Cleveland.Braintree 851 caccagogues and effect.Gastroenterology (gastroenterology) rolls up 112:A722,1997.
P.Culbert, H.Gillett, the high-efficient oral therapy (Polyethylene Glycol/electrolyte solution) of A.Ferguson. fecal impaction and serious constipation.Clinical Drug Investigation, (clinical drug research), volume 16:355-360,1998.
A.Attar, M.Lemann, A.Ferguson, M.Halphen, M.-C.Boutron, B.Flourie, E.Alix, M.Salmeron, F.Guillemot, S.Chaussade, A.-M.Menard, J.Moreau, G.Naudin, the low dosage polyethylene glycol electrolyte solution that M.Barthet. treatment chronic constipation is used and the contrast of lactulose.Gut, volume 44:226-230,1999.
Therefore, one aspect of the present invention is to use a kind of osmosis compositions, and said composition contains system (preferred PEG 3350 NF based on Polyethylene Glycol, or PEG 4000 NF), and made up a kind of effervescent coupling system, with the liquid of proper volume, as water or juice dilution.
The effervescent coupling agent comprises a kind of alkaline components and a kind of acid ingredient, and when alkaline components contacted with the water of adding with acid ingredient, alkaline components can discharge carbon dioxide.
The selection of effervescent coupling agent consumption itself can not make to be enough to cause a kind of " reaction of the foaming sound of neighing " and produce discomfort degree of being in patient's mouth.
The effervescent coupling agent typically comprises citric acid or natrium hydrocitricum and sodium bicarbonate, but also can use the carbonate mixture of acceptable acid/alkali metal of other physiology or alkaline-earth metal, for example tartaric acid, adipic acid, fumaric acid or maleic acid and carbonic acid (hydrogen) sodium, potassium or calcium, or sodium glycine carbonate.
In a word, have been found that, when effervescent coupling agent two components are that the relative scale of benchmark is 3: 1～3: 4 with the chemical molecular equivalent, more preferably from about 1.4～1.9: 1 o'clock, demonstrate taste profile preferably, this schedule of proportion is shown the molecule equivalent proportion of basic component and acidic components, and wherein basic component is sodium bicarbonate (NaHCO 3), acidic components are citric acids.But, compare with many well-known effervescent systems, can use the bicarbonate and the citric acid of much less.Embodiment herein will illustrate the utilization of high level and low-level effervescent coupling agent.According to a preferred compositions of sodium bicarbonate and citric acid, these values are benchmark with weight, represent 3: 1～0.6-0.8: 1, and preferred about 1: 1, the ratio of expression alkali and acid constituents.
But, in some prescription, when acidic components are excessive, for example, be benchmark with the chemical molecular equivalent, when the ratio of acidic components and basic component is about 11: 3～4: 3, select flavouring agent can make taste profile reach optimization.With regard to the combination of citric acid and sodium bicarbonate, this can represent 5: 1～1: 1 weight ratio.
The weight of acidic components can be 7%-31% in the prescription, preferred 9%-18%, all by weight.
The weight of prescription neutral and alkali component can be 7%-32%, preferred 9%-18%, all by weight.
Preferred combination comprises 2: 1～sodium bicarbonate and the citric acid (or natrium hydrocitricum) or the maleic acid of 1: 1 weight ratio.
Other preferably makes up can use potassium bicarbonate instead of part or whole sodium bicarbonate as the basic component in the effervescent coupling agent.In order to keep equimolecular quantity, its ratio is about 1.2: 1 when replacing sodium bicarbonate with potassium bicarbonate.Potassium bicarbonate can use together with above-mentioned any acid constituents.
The coupling agent that effervescent mixture is used, the preferable amount level of preferred bicarbonate and citrate are about 2.3 to exempt from NaHCO 3(sodium bicarbonate) and 2.2 gram citric acids.This dosage provides very significantly ANC (acid neutralization capacity), about 20mEq.But this consumption level can reduce 4-5 doubly, and to a certain degree effervescent effect (0.5g NaHCO for example still can be provided 3With the 0.4g citric acid).
Know, can add extra excipient in the said preparation, as flavouring agent, coloring agent, sweeting agent, antioxidant, and other helps additives known stable and packing.
Preferred PEG used herein is PEG 3350, and it is that a kind of molecular weight is about 3,000 the inert polymer that can not absorb.Usually, for the liquid reorganization of 125-240ml, the amount ranges of PEG 3350 is about 5 Ke-Yue 30 grams, about 20 grams of preferably about 10-, more preferably 13-17 gram.Treatment can be every day 1 time or several times, every days 4 times at most, but preferred every day 1 time.
Opposite with fluffy fiber, resulting preparation based on effervescent/PEG is a non-sticky when making liquid dosage form, and preferably with the bulky powder form, or preferably be supplied to consumer with unit-dose powder sachet form, be convenient to be dissolved in suitable liquid such as water or the syrup.This product can dissolve (in the several seconds) and fully fast, and can retrogradation when leaving standstill.
Based on the volume that is consumed (for example dosage of 1 or 2 4-8 ounce), performance characteristic and desired consistent (the acting on soon of present zest caccagogue user, remove clean), yet but do not have the negative side-effects of cramp and gas, and the potential harmful chemicals that does not have general to expose.
Required dosage can equal " minimum effect dosage " when the caccagogue, promptly requires 2-3 days the required dosage of treatment before the positive effect that has to outbreak similar based on the caccagogue of fluffy fiber and effect.Perhaps this dosage can be increased to from use read fortune when at present based on the product of stimulant, it have early begin effect (several hours to a night).
The present invention can be used as sporadic and main treatment means chronic constipation, and is used for the treatment of fecal impaction (with higher dosage).Another aspect of the present invention is the treatment top gastrointestinal symptom relevant with this constipation, as heartburn or flatulence.Where applicable, compositions of the present invention also can be used for treating other disease relevant with constipation, as allergic intestinal syndrome, diverticulum disease and hemorrhoid.
Formulation method
The following examples further specify the present invention, but are not intended to limit its scope.All umbers and percentage number average refer to weight, but have except the person of indicating in addition.
Embodiment 1
A preferred embodiment provides the caccagogue that can reassemble in 240ml water with the sachet form.The PEG system:
17.0g Polyethylene Glycol (PEG) 3350 NF effervescent coupling agents:
1.50g NaHCO 3
1.00g citric acid
This PEG solution and effervescent coupling system are merged and be packaged into sachet, join in the glass of 8 ounces of water when preparing to use.
Embodiment 2
Another preferred embodiment provides the caccagogue that can reassemble in 240ml water with the sachet form.The PEG system:
17.0g Polyethylene Glycol (PEG) 3350 NF effervescent coupling agents:
2.32g NaHCO 3
2.18g citric acid
This PEG solution and effervescent coupling system are merged and be packaged into sachet, join in the glass of 8 ounces of water when preparing to use.
Embodiment 3
Another preferred embodiment provides the caccagogue that can reassemble in 125-180ml water with the sachet form.The PEG system:
13.12g?PEG?3350
0.78g flavor component effervescent coupling agent:
2.32g NaHCO 3
2.18g citric acid
This PEG solution and effervescent coupling system are merged and be packaged into sachet, join in the glass of 4-6 ounce water when preparing to use.
Embodiment 4
Another preferred embodiment provides the caccagogue that can reassemble in 125-180ml water with the sachet form.The PEG system:
13.12g?PEG?3350
0.78g flavor component effervescent coupling agent:
1.50g NaHCO 3
1.00g citric acid
This PEG solution and effervescent coupling system are merged and be packaged into sachet, join in the glass of 4-6 ounce water when preparing to use.
Embodiment 5
The caccagogue that can reassemble in 125-200ml water is provided with the sachet form.The PEG system:
8.5g?PEG?3350
0.06g fragrance mixture (being used for aroma product) effervescent coupling agent:
2.32g NaHCO 3
2.18g citric acid
This PEG solution and effervescent coupling system are merged and be packaged into sachet, join in the glass of 4-6 ounce water when preparing to use.
Embodiment 6
The caccagogue that can reassemble in 125-200ml water is provided with the sachet form.The PEG system:
8.5g?PEG?3350
0.06g fragrance mixture (being used for aroma product) effervescent coupling agent:
1.50g NaHCO 3
1.00g citric acid
This PEG solution and effervescent coupling system are merged and be packaged into sachet, join in the glass of 4-6 ounce water when preparing to use.
Embodiment 7
The caccagogue that can reassemble in 125-200ml water is provided with the sachet form.The PEG system:
13.125g PEG 3350 effervescent coupling agents:
2.32g NaHCO 3
2.18g citric acid
This PEG solution and effervescent coupling system are merged and be packaged into sachet, join in the glass of 4-6 ounce water when preparing to use.
Embodiment 8
The caccagogue that can reassemble in 125-200ml water is provided with the sachet form.The PEG system:
13.125g PEG 3350 effervescent coupling agents:
1.50g NaHCO 3
1.00g citric acid
This PEG solution and effervescent coupling system are merged and be packaged into sachet, join in the glass of 4-6 ounce water when preparing to use.
Embodiment 7
The caccagogue that can reassemble in 125-200ml water is provided with the sachet form.The PEG system:
13.125g PEG 3350 effervescent coupling agents:
2.32g NaHCO 3
2.18g citric acid
This PEG solution and effervescent coupling system are merged and be packaged into sachet, join in the glass of 4-6 ounce water when preparing to use.
All publications of quoting in this description include, but are not limited to patent and patent application and all incorporate this paper into as a reference, are specified particularly and one by one in full as each publication and incorporate this paper into as a reference.
Above-mentioned explanation fully discloses the present invention, comprises its preferred specific embodiments.Modification of concrete disclosed embodiment herein and improvement all drop in the scope of following claims.Need not to describe in further detail, can believe, art technology person farthest utilizes the present invention surely after the explanation of having read the front.Therefore, embodiment provided here is illustrative, in any case also do not constitute limitation of the scope of the invention.Require the specific embodiments of the present invention of exclusiveness right or privilege to define by following claim.

Claims (10)

1. pharmaceutical preparation wherein comprises a kind of Polyethylene Glycol (PEG) 3350 of infiltration capacity or PEG 4000 and a kind of pharmaceutically acceptable effervescent coupling system.
2. according to the preparation of claim 1, wherein this effervescent coupling agent constitutes about 10-about 30% of said preparation gross weight.
3. according to the preparation of claim 1, wherein this effervescent coupling agent comprises a kind of citric acid, tartaric acid, adipic acid, fumaric acid, maleic acid of being selected from, or its acid salt, or the acid constituents of its mixture.
4. according to the preparation of claim 1, wherein this effervescent coupling agent comprises and a kind ofly is selected from carbonic acid (hydrogen) sodium, potassium or calcium, or the basic component of sodium glycine carbonate.
5. according to any one preparation among the claim 1-4, it also comprises one or more flavouring agents, coloring agent or sweeting agent.
7. according to the preparation of claim 1, the amount of PEG is the 0.75-30 gram in wherein every dosage unit.
8. according to the preparation of claim 1, the amount of PEG is the 10-20 gram in wherein every dosage unit.
9. method for the treatment of constipation in the mammal, this method comprise to described mammal effective dosage according to any one preparation among the claim 1-8.
10. method for the treatment of fecal impaction in the mammal, this method comprise to described mammal effective dosage according to any one preparation among the claim 1-8.
11. one kind according to any one preparation among the claim 1-6, wherein said preparation is dosage unit sachet form.
CN00804156A 1999-02-22 2000-02-22 Effervescent laxatives Pending CN1341016A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12108999P 1999-02-22 1999-02-22
US60/121089 1999-02-22

Publications (1)

Publication Number Publication Date
CN1341016A true CN1341016A (en) 2002-03-20

Family

ID=22394460

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00804156A Pending CN1341016A (en) 1999-02-22 2000-02-22 Effervescent laxatives

Country Status (14)

Country Link
EP (1) EP1154765A4 (en)
JP (1) JP2002537248A (en)
KR (1) KR20010102323A (en)
CN (1) CN1341016A (en)
AU (1) AU3604600A (en)
BR (1) BR0008385A (en)
CA (1) CA2362355A1 (en)
CZ (1) CZ20013043A3 (en)
EA (1) EA003064B1 (en)
HK (1) HK1043046A1 (en)
HU (1) HUP0105351A3 (en)
PL (1) PL349360A1 (en)
WO (1) WO2000048585A1 (en)
ZA (1) ZA200106888B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101002832B (en) * 2006-09-02 2011-01-05 江西农业大学 Granulated quickly dissolving medicine for relaxing bowel

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048901A (en) * 1999-04-20 2000-04-11 Braintree Laboratories, Inc. Method of reducing intestinal gas, cramping and anorectal irritation
DE102004023288A1 (en) * 2004-05-11 2005-12-15 Stefan Spiess Macrogol preparation
EP1835854A4 (en) * 2004-12-30 2008-03-05 Given Imaging Ltd Device, system and method for in-vivo examination
AU2010239378B2 (en) 2009-04-21 2013-11-21 Dark Canyon Laboratories, Llc Colon lavage system
CN103391790B (en) * 2011-01-28 2016-06-15 布伦特里实验室有限公司 For the method for intestinal tract cleaning, composition and packaging
WO2013067424A1 (en) * 2011-11-06 2013-05-10 Ssv Therapeutics, Llc Formulations of concentrated prunes and prebiotics as laxatives and dietary supplements

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB942743A (en) * 1959-05-22 1963-11-27 Welloome Foundation Ltd Oestrogen preparations and the manufacture thereof
GB1518364A (en) * 1976-05-05 1978-07-19 Beecham Group Ltd Pharmaceutical composition
US4093710A (en) * 1976-07-07 1978-06-06 Sandoz, Inc. Rapid dissolving effervescent granules
JPH01283222A (en) * 1988-05-10 1989-11-14 Tokai Kapuseru Kk Soft capsule agent of sodium picosulfate
IT1229568B (en) * 1989-04-17 1991-09-04 Giuliani Spa PHARMACEUTICAL COMPOSITION FOR ORAL USE SUITABLE FOR USE IN GASTRO-INTESTINAL WASHING, IN PARTICULAR FOR DIAGNOSTIC USE, OR AS A CATHARTIC LAXATIVE.
US4946939A (en) * 1989-05-30 1990-08-07 The Dow Chemical Company High purity polyether polyols
US5710183A (en) * 1995-07-14 1998-01-20 Halow; George M. Laxative/antidiarrheal composition comprising polyethylene glycol and fiber bulking agent
US6048901A (en) * 1999-04-20 2000-04-11 Braintree Laboratories, Inc. Method of reducing intestinal gas, cramping and anorectal irritation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101002832B (en) * 2006-09-02 2011-01-05 江西农业大学 Granulated quickly dissolving medicine for relaxing bowel

Also Published As

Publication number Publication date
HUP0105351A3 (en) 2004-06-28
CA2362355A1 (en) 2000-08-24
ZA200106888B (en) 2002-09-27
PL349360A1 (en) 2002-07-15
AU3604600A (en) 2000-09-04
WO2000048585A1 (en) 2000-08-24
EP1154765A1 (en) 2001-11-21
CZ20013043A3 (en) 2001-11-14
HK1043046A1 (en) 2002-09-06
HUP0105351A2 (en) 2002-05-29
KR20010102323A (en) 2001-11-15
EA003064B1 (en) 2002-12-26
EA200100785A1 (en) 2002-04-25
BR0008385A (en) 2002-01-29
EP1154765A4 (en) 2004-12-01
JP2002537248A (en) 2002-11-05

Similar Documents

Publication Publication Date Title
EP1742645B1 (en) Compressed pharmaceutical compositions comprising peg and electrolytes
EP2308476B1 (en) Colonic purgative composition with soluble binding agent
CN1101187C (en) Fluoxetine pahrmaceutical formulations
MXPA06010295A (en) Concentrated neutral detergent composition.
US6444198B1 (en) Effervescent laxatives
CN1248681C (en) Solid orally-dispersible pharmaceutical formulation
JP4276545B2 (en) Improved composition
JP2000302686A (en) Reduction in intestinal gas, convulsion and anorectal anaphylaxis
CN1341016A (en) Effervescent laxatives
US10617761B2 (en) Compositions and solutions for colon cleansing
JP6585053B2 (en) Gastric retention oral pharmaceutical composition
IES20110480A2 (en) A solid formulation for oral administration comprising polyethylene glycol and mannitol
AU2011100528A4 (en) Formulations
MXPA01008492A (en) Effervescent laxatives
IE20110480U1 (en) A solid formulation for oral administration comprising polyethylene glycol and mannitol
IES86031Y1 (en) A solid formulation for oral administration comprising polyethylene glycol and mannitol

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication